Adaptive Pathways: Possible Next Steps for Payers in Preparation for Their Potential Implementation

Adaptive Pathways: Possible Next Steps for Payers in Preparation for Their Potential Implementation

Medicines receiving a conditional marketing authorization through Medicines Adaptive Pathways to Patients (MAPPs) will be a challenge for payers. The “introduction” of MAPPs is already seen by the European Medicines Agency (EMA) as a fait accompli, with payers not consulted or involved. However, onc...

Full description

Bibliographic Details
Main Authors: Patricia Vella Bonanno, Michael Ermisch, Brian Godman, Antony P. Martin, Jesper Van Den Bergh, Liudmila Bezmelnitsyna, Anna Bucsics, Francis Arickx, Alexander Bybau, Tomasz Bochenek, Marc van de Casteele, Eduardo Diogene, Irene Eriksson, Jurij Fürst, Mohamed Gad, Ieva Greičiūtė-Kuprijanov, Martin van der Graaff, Jolanta Gulbinovic, Jan Jones, Roberta Joppi, Marija Kalaba, Ott Laius, Irene Langner, Ileana Mardare, Vanda Markovic-Pekovic, Einar Magnusson, Oyvind Melien, Dmitry O. Meshkov, Guenka I. Petrova, Gisbert Selke, Catherine Sermet, Steven Simoens, Ad Schuurman, Ricardo Ramos, Jorge Rodrigues, Corinne Zara, Eva Zebedin-Brandl, Alan Haycox
Format: Article
Language:English
Published: Frontiers Media S.A. 2017-08-01
Series:Frontiers in Pharmacology
Subjects:
European Medicines Agency
Adaptive Pathways
Health Technology Assessment
marketing authorization
payers
Online Access:http://journal.frontiersin.org/article/10.3389/fphar.2017.00497/full

Internet

http://journal.frontiersin.org/article/10.3389/fphar.2017.00497/full

Similar Items